BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 16, 2023
Discovery & Translation

Aldena’s JAK-1-selective siRNA; an aerosol mAb for SARS-CoV-2 and more

BioCentury’s roundup of translational innovations
BioCentury | Dec 31, 2020
Distillery Therapeutics

Agonizing adiponectin receptors to treat NASH, liver fibrosis

DISEASE CATEGORY: Hepatic
INDICATION: Non-alcoholic steatohepatitis (NASH); liver fibrosis An ADIPOR1 and ADIPOR2 dual agonist based on the endogenous adipocytokine adiponectin could treat
BioCentury | Jun 19, 2006
Product Development

Showcasing new diabetes targets

Items per page:
1 - 3 of 3